Publicaciones en colaboración con investigadores/as de Hadassah Medical Center (23)

2023

  1. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

    Neuro-oncology, Vol. 25, Núm. 1, pp. 37-53

  2. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  2. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

    British Journal of Haematology, Vol. 194, Núm. 1, pp. 132-139

2020

  1. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1850-1859

2018

  1. A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

    Haematologica, Vol. 103, Núm. 8, pp. 1351-1358

  2. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

    Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227

  3. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

    Nature Medicine, Vol. 24, Núm. 12, pp. 1867-1876

2017

  1. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

    Leukemia, Vol. 31, Núm. 1, pp. 107-114

  2. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

    Blood, Vol. 130, Núm. 24, pp. 2610-2618

  3. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  4. Predictors of responses to immune checkpoint blockade in advanced melanoma

    Nature Communications, Vol. 8, Núm. 1

2016

  1. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma

    New England Journal of Medicine, Vol. 375, Núm. 14, pp. 1319-1331

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2009

  1. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

    British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903

2008

  1. Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study

    Leukemia, Vol. 22, Núm. 4, pp. 842-849

2007

  1. Computed tomographic screening for lung cancer: Individualising the benefit of the screening

    European Respiratory Journal, Vol. 30, Núm. 5, pp. 843-847

  2. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

    Blood, Vol. 110, Núm. 10, pp. 3557-3560